Abstract
In this chapter, we first consider the overall goal of nonclinical safety testing during drug development and have a brief overview of its regulatory background. We then discuss some basic requirements of safety/toxicity testing before concentrating on the safety testing of RNA vaccines and developing a sample RNA vaccine safety testing program.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
ICH M3(R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, p 2. http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html. Accessed 29 Oct 2015
Hager GH (2011) A checklist of some general basic requirements for starting toxicity studies of a New Chemical Entity (NCE). In: Company folder preclinical safety testing. Aurigon Life Science GmbH, Munchen
Hager GH (2011) A checklist of some general basic requirements for starting toxicity studies for New Biological Entities (NBE). In: Company folder preclinical safety testing. Aurigon Life Science GmbH, Munchen
Aurigon Life Science GmbH (2010) Sample study plan. Aurigon Life Science GmbH, Munchen
Aurigon Life Science GmbH (2010) Sample study report. Aurigon Life Science GmbH, Munchen
World Health Organization: Annex 1 who guidelines on nonclinical evaluation of vaccines, p 9. http://www.who.int/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation/en/. Accessed 29 Oct 2015
European Medicines Agency EMA: guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products (EMEA/CHMP/GTWP/125459/2006). http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000410.jsp&mid=WC0b01ac058002958d. Accessed 29 Oct 2015
World Health Organization: Annex 1 WHO guidelines on nonclinical evaluation of vaccines, pp 10–11. http://www.who.int/biologicals/publications/trs/areas/vaccines/nonclinical_evaluation/en/. Accessed 29 Oct 2015
Acknowledgements
The author thanks Helga Bleuel for her helpful comments during the preparation of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Hager, G. (2017). Nonclinical Safety Testing of RNA Vaccines. In: Kramps, T., Elbers, K. (eds) RNA Vaccines. Methods in Molecular Biology, vol 1499. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6481-9_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6481-9_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6479-6
Online ISBN: 978-1-4939-6481-9
eBook Packages: Springer Protocols